Navigation Links
Colorectal Cancer Survival Rates Poorer in African-Americans

A new Study led by Chyke A. Doubeni, M.D., M.P.H. of the University of Massachusetts Medical School and the Meyers Primary Care Institute in Worcester, MA, researchers from// the National Cancer Institute-funded Cancer Research Network investigated the association between tumor stage and risk of death by race in colorectal cancer and factors related to ethnic/racial differences in a population of insured persons.

According to the study, African-Americans with health insurance still face worse outcomes in colorectal cancer than Caucasians, Hispanics, and Asians. Published in the February 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that differences in utilization of screening tests and surgical treatment may contribute to poorer colorectal cancer survival rates in African-Americans.

Colorectal cancer is preventable and even curable. Improvements in the sensitivity and specificity of screening tests and in treatment protocols have resulted in overall declines in mortality rates for colorectal cancer. However, studies have demonstrated and continue to show clear ethnic/racial differences in survival. African-Americans have the worst outcome of any ethnic/racial group, while Caucasians tend to fare worse than Asians. Access to healthcare is often cited as the cause of these disparities. In fact, studies show that, in general, people with health insurance are more likely to access preventive care than those without. However, the impact of health insurance and potential access has on colorectal cancer mortality by race has not been explored to date.

The authors found that African-Americans were more likely to have advanced disease and were at greatest risk of death compared to other ethnicities/races. Caucasians and Hispanics had similar cancer mortality risks, and Asians and Pacific Islanders were least likely to die of the cancer. In addition, African-Americans were less likely to recei
'"/>




Page: 1 2

Related medicine news :

1. Detecting Colorectal Cancer
2. Preventing Colorectal Cancer
3. Screening Test For Early Diagnosis Of Colorectal Cancer
4. Milk Found To Lower Colorectal-Cancer Risk By 12 %
5. New Treatment Option for Colorectal Cancer
6. Alcohol Consumption A Threat To Colorectal Tumours
7. Alcohol Drinking Affects Risk Of Colorectal Tumours
8. Women More Prone To Risk of Colorectal Cancer from Tobacco
9. Meta Analysis Links Diabetes And Colorectal Cancer
10. Colorectal Cancer Can Be Detected By a Simple Test
11. Smoking and Drinking Could Lead Colorectal Cancer

Post Your Comments:
(Date:11/25/2009)...BroadPoliticalEndorsements,Business,andPressJoinEf...re-USNewswire/--Onceagain,theNationalBipolarFounda...endorsingtheir"Safe,tilStable"program,whichisnowbe...bipolardisorder.Today,theNationalBipolarFoundation...sPriorityMailfromtheLt.GovernorofLouisianaMitchLan...
(Date:11/25/2009)...tuitous discovery that grew out of a collaboration...tially offer hope to the nearly 10 million America... , Also known as hardening of the arteries, per...ulatory problem in which narrowed arteries reduce ...ed a red flag for vascular disease, heart attack a...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
(Date:11/25/2009)... often plagued by neurological symptoms, study fin...ws) -- Neurological side effects are among the pot...sticular cancer who were treated with cisplatin-ba...study included 1,409 Norwegian men treated for uni...o took part in a follow-up survey conducted from 1...
(Date:11/25/2009)...RLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAme...ealthCareFraudActof2009,"S.2128,whichisdesignedtos...ventfraudinMedicare.ThebillwasintroducedbySen.Geor...eralprovisionstheAmericanAssociationforHomecareout...ociationproposedtoCongressinFebruary.Thoseprovisio...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...itute for Biological Studies during embryonic deve...produce// tentacle-like protrusions. These are cal...r destination. They guide the nerve cells through ...in the limb, scientists at the Salk Institute for ...
...s on obesity finalized to cause harm to children, .... Due to financial agreements made between t...ing this proposal, an unfit guideline was being ma...rican Medical Association has ‘tentatively decided...
...n makes women more disabled than men – study publi...s treatment procedures targeting to reduce stress ...reduce disability. This suggests that by targe... which involved 260 chronic pain patients from Roy...
...act fast when their reputation is at stake. Now th...nd credibility by doing something solid about all ...hicken, Wendy's, McDonald's and Burger King are al...nt. Jeff O'Neill, president and chief operat...
...omen, women overweight in their teens or later are...r. // This research was conducted by scientists at...The participants of the study were some 2,110 wome... were more likely to develop the disease compared ...
... portion of the horses in the Meath/Kildare region...g to reports from The Department of Agriculture an...ne Infectious Anemia, has an incubation period of ...s are being conducted to ascertain the facts. Ther...
Other Medicine News:Health News:Growth Factors Help Neurons to Reach Their Correct Destination 2Health News:Growth Factors Help Neurons to Reach Their Correct Destination 3Health News:New Obesity Guidelines Will Trouble US Children 2Health News:Depression And Chronic Pain Cause Disability In Women 2
(Date:11/25/2009)...rstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),aclinical...evelopingandcommercializingnoveldrugstotreatvirali...endedSeptember30,2009.AtSeptember30,2009Pharmasset...investments. ,, PipelineUpdateand2009Highlight...ateNovember2009,anindependentDataMonitoringCommitt...
(Date:11/25/2009)...PRNewswire/-- FromNovember16-18,Phonak,theleadingm...hesecondeditionoftheHearingCareforAdultsConference...conferencebroughttogetherleadingexpertsinaginganda...whoworkeverydaywitholderpeoplewithhearinglossforan...searchandtrendsinhearingcareforolderpeople. ,,...
(Date:11/25/2009)...--TheFDAgrantedtraditionalapprovalforINTELENCE...riptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTIspe...ltswhoareexperiencingvirologicfailurewithHIV-1stra...ents.Thetraditionalapprovalisbasedon48-weekdatafro...scurrentlymarketedintheU.S.byTibotecTherapeutics,a...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 1Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 6The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 1The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 2ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 1ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 2
... Therapeutics, Inc. (Nasdaq: TPTX ) today announ...ial evaluating three doses of NGX267 as a treatmen...jogren,s syndrome. NGX267 met the primary endpoin...ary flow production compared to placebo at all thr...e safe and well tolerated with few reports of exce...
... (Nasdaq: MITI ), a biopharmaceutical company de...atment of cancer, inflammation and autoimmune dise...agreement expanding its Committed Equity Financing... a private investment group. Under the terms of t... up to $75 million of capital during the next thre...
Other Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: